Logan Lutton

Here’s what you missed this week on Managed Healthcare Executive.

Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the importance of preexposure anaphylaxis and why he’s hesitant to jump on the Lenacapavir breakthrough bandwagon.

The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).

In this interview, Sarah Morris, chief product officer of Audere, explains why they chose to focus on women and young girls and how they have tailored their program to reach them.

A scleroderma patient in a Sylvester Comprehensive Cancer Center trial was recently successfully treated with CAR T-cell lymphoma therapy, in what researchers are calling an “immunological reset.”

Audere is closing gaps in HIV care and education with the help of Aimee, their artificial intelligence companion designed to reach women and young girls in South Africa, according to Sarah Morris, CPO of Audere.

Humana has released details about additional, upcoming organizational improvements to encourage a faster prior authorization process, lessen system waste and increase transparency.

This biosimilars market report focuses on rising market complexity and recent activity, including two new approvals and four launches in Q2.

A national preexposure prophylaxis (PrEP) program would streamline access and improve HIV outcomes but unfortunately never came to pass because of a lack of funding, according to Jeremiah Johnson, executive director, PrEP4All.

Here’s what you missed this week on Managed Healthcare Executive.

Although the FDA approval of lenacapavir as a twice-yearly form of preexposure prophylaxis (PrEP) is “momentous,” cost and access curb excitement, according to Jeremiah Johnson, executive director of PrEP4All.

The high cost of pharmaceutical products coupled with a lack of federally funded HIV programs create barriers for preexposure prophylaxis (PrEP) access according to Jeremiah Johnson, executive director, PrEP4All.

Autoimmune diseases, such as vitiligo, celiac disease and rheumatoid arthritis, are not tied to aluminum exposure from vaccines, according to a nationwide cohort study of approximately 1.2 million children done in Denmark.

A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said there were more risks than benefits for menopausal women taking hormone therapy.

This new Shingrix vaccine presentation eliminates the need for reconstitution, simplifying the administration process for healthcare professionals.

Integrating people-centered HIV care with primary health care is essential to improving access, equity and health outcomes, but doing so successfully requires coordinated policies, digital transformation, community engagement, and sustained funding, according to experts at IAS 2025.

While successes have been seen because of HIV self-testing, funding cuts to USAID and PEPFAR will make continued research difficult, according to Anna Bershteyn, Ph.D., associate professor in the Department of Population Health, NYU Grossman School of Medicine.

In this interview, Matthew Yarnell, president of SEIU Healthcare, Pennsylvania, a healthcare union, condemns Trump’s $1 trillion Medicaid cut, saying that more than a quarter of a million Pennsylvanians will lose their healthcare coverage as a result.

The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its impact depends on access, patient-centered care and affordability.

Integrating HIV and sexual health care is essential for improving outcomes, but global stigma, funding cuts—especially the defunding of USAID—and structural barriers like limited access and political resistance continue to hinder progress, experts emphasized at IAS 2025.

There is currently a movement to “de-medicalize" PrEP by pushing for more availability at more casual settings than government clinics, according to Anna Bershteyn, Ph.D., associate professor in the Department of Population Health, NYU Grossman School of Medicine.

The most common HIV antibody blood test is called an “A-0” test, which is available for approximately 70 cents in many low- and middle-income countries, according to Anna Bershteyn, Ph.D., associate professor in the Department of Population Health, NYU Grossman School of Medicine.

Here’s what you missed this week on Managed Healthcare Executive.

A new survey by eHealth and Retirable finds that 80% of Americans worry Medicare and Social Security won’t be available when they need them, amid projections that both trust funds could be depleted by 2034.

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, according to the Merck news release.

Period-induced alcohol cravings and societal changes are contributing to a rising trend in women drinking, according to new research from Sarah McKetta, M.D., Ph.D., assistant professor, Mailman School of Public Health, Columbia University and Layne Robinson, clinical psychology doctoral student and graduate research assistant in the RISK Laboratory, University of Kentucky.

Menopause therapy coverage varies by insurance type and is dependent on FDA approval status, clinical guidelines and prior authorizations, all of which are best navigated with the help of a managed care pharmacy expert, according to Susan Cantrell, CEO, Academy of Managed Care Pharmacy.

The prevalence of autoimmune disease patients with a mental health disorder is almost twice the number of patients without, suggesting there is a link between inflammation and conditions such as depression, anxiety disorder and bipolar disorder.

Orsini will be the specialty pharmacy partner for Ekterly.